ADARx Pharmaceuticals Q3 2026 Results and IPO Details
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
ADARx Pharmaceuticals Reports Third Quarter 2026 Results and Successful IPO
SAN DIEGO, Calif. - ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a biotechnology company specializing in next-generation siRNA therapeutics, has announced its financial results for the third quarter ended September 30, 2026, alongside key business updates. The company highlighted significant milestones, most notably the successful completion of an initial public offering (IPO) and a concurrent private placement, which generated aggregate gross proceeds of approximately $602.5 million. This capital infusion is expected to extend the company's operational runway into 2030.
Clinical Development Highlights
... Read on — Members only
